Passage BIO PASG
NASDAQ PASG
$4.44 -0.04 (-0.89%)
At close: Aug 21, 2026 · 4:00 PM EDT

Passage BIO (PASG) Non Operating Investment Income (2020 - 2021)

Passage BIO (PASG) posted quarterly Non Operating Investment Income of -$5000.0 for Q1 2021, up 82.14% quarter-over-quarter from -$28000.0 in Q4 2020.

Passage BIO (PASG) Non Operating Investment Income (2020 - 2021) Analysis & Trends

Passage BIO's Non Operating Investment Income history runs 2 years deep, the most recent figure standing at -$5000.0 for Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Passage BIO 13.99 Mn 13.99 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 -5,000.00
Mar 31, 2021 -5,000.00
Dec 31, 2020 -28,000.00
Dec 31, 2020 -28,000.00
Sep 30, 2020 40,000.00
Sep 30, 2020 40,000.00